Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/26/18
End: 12/31/20
Due: 12/31/21
Phase: N/A
Priority: Normal
Start: 11/30/14
End: 07/31/16
Due: 07/31/17
Phase: N/A
Priority: Normal
Start: 02/22/19
End: 12/31/24
Due: 12/31/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed | NCT04132674 | Vancouver Infectious Diseases Centre | user2@example.com | None | 2018-11-26 | 2020-12-31 | 2021-12-31 | - | - | 2025-07-14 |
| STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY) | NCT02306577 | Vancouver Infectious Diseases Centre | user2@example.com | None | 2014-11-30 | 2016-07-31 | 2017-07-31 | - | - | 2025-07-14 |
| Eliminating HCV Infection Among PWUD | NCT05474781 | Vancouver Infectious Diseases Centre | user2@example.com | None | 2019-02-22 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |